New weekly shot could help chinese adults shed pounds and control diabetes
NCT ID NCT07670416
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This phase 3 trial is testing a once-weekly injection called enicepatide in 300 Chinese adults who are obese or overweight, with or without type 2 diabetes. The drug works by mimicking two gut hormones to reduce appetite and improve blood sugar control. Participants will receive either the drug or a placebo, along with diet and exercise advice, for 52 weeks to see how much weight they lose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Enicepatide (a weekly injection that targets two gut hormones to reduce appetite and improve blood sugar)
- What this could lead to
- If successful, this could offer a new once-weekly injection to help Chinese adults with obesity or overweight lose significant weight and manage type 2 diabetes.
- What could go wrong
- This is a phase 3 trial, but results may not apply to other populations. Side effects like nausea or vomiting are common with this drug class, and long-term safety is still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hebei Medical University - The Second Hospital
RECRUITINGShijiazhuang, 050004, China
-
Hebei Petro China Central Hospital
RECRUITINGLangfang, 065000, China
-
Huai'an First People's Hospital
RECRUITINGHuai'an, DUMMY_VALUE, China
-
Huzhou Central Hospital
RECRUITINGHuzhou, 313000, China
-
Jinan Central Hospital
RECRUITINGJinan, 250013, China
-
Luoyang Third People's Hospital
RECRUITINGLuoyang, 471000, China
-
Peking University People's Hospital
RECRUITINGBeijing, 100044, China
-
Shanghai East Hospital
RECRUITINGShanghai, 200120, China
-
Shanghai Fifth People's Hospital Affiliated to Fudan University
RECRUITINGShanghai, 201304, China
-
Shanghai Tenth People's Hospital
RECRUITINGShanghai, 200072, China
-
Shenyang Fifth People Hospital
RECRUITINGShenyang, 110074, China
-
The Affiliated Jiangning Hospital of Nanjing Medical University
RECRUITINGNanjing, 211100, China
-
The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)
RECRUITINGNingbo, Zhejiang, 315010, China
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, 230601, China
-
The Second Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450014, China
-
Tongren Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, 200336, China
-
Yan'an University Xianyang Hospital
RECRUITINGXianyang, Shaanxi, 712000, China
-
Zibo Municipal Hospital.
RECRUITINGZibo, 255400, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?